- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07476287
Symbiotic-Lung-14: 변형 소세포폐암 성인 참가자를 대상으로 화학요법과 병용 투여되는 PF08634404 연구 의약품에 관한 연구
이전에 치료받지 않은 변형 소세포폐암 환자에서 PF-08634404와 화학요법의 병용에 관한 2상 중재 연구
This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. The study is for adults with Transformed Small Cell Lung Cancer (T-SCLC ). T SCLC is a rare lung cancer that happens when one type of lung cancer changes into a more aggressive type after treatment stops working.
To join the study, participants must meet the following conditions:
- Are aged 18 years or older
- Diagnosed with T-SCLC and have not received treatment for this type of lung cancer (a single cycle of chemotherapy may be permitted)
- Prior diagnosis of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors (TKIs)
- Have healthy organs based on medical tests and are in good physical condition
After joining the study, adults will be given chemotherapy in addition to the study medicine. After this combination treatment is finished, the study medicine will be continued alone. Adults will receive the treatment through IV infusions (medicine given directly into a vein). All treatments will be done at clinical study sites, where a trained medical team will monitor adults during and after each visit.
연구 개요
상태
개입 / 치료
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Pfizer CT.gov Call Center
- 전화번호: 1-800-718-1021
- 이메일: ClinicalTrials.gov_Inquiries@pfizer.com
연구 장소
-
-
-
Tainan, 대만, 704302
- 모병
- National Cheng Kung University Hospital
-
Taipei, 대만, 100
- 모병
- National Taiwan University Hospital
-
Taipei, 대만, 11217
- 모병
- Taipei Veterans General Hospital
-
Taipei, 대만, 106
- 모병
- National Taiwan University Cancer Center (NTUCC)
-
-
-
-
California
-
Duarte, California, 미국, 91010
- 모병
- City of Hope National Medical Center
-
Encinitas, California, 미국, 92024
- 모병
- UC San Diego Medical Center - Encinitas
-
Irvine, California, 미국, 92618
- 모병
- City of Hope Lennar Foundation Cancer Center
-
La Jolla, California, 미국, 92037
- 모병
- UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)
-
La Jolla, California, 미국, 92037
- 모병
- UC San Diego Sulpizio Cardiovascular Center
-
La Jolla, California, 미국, 92037
- 모병
- UC San Diego Moores Cancer Center
-
La Jolla, California, 미국, 92037
- 모병
- UC San Diego Koman Family Outpatient Pavilion
-
San Diego, California, 미국, 92101
- 모병
- UC San Diego Medical Center - Bankers Hill
-
San Diego, California, 미국, 92103
- 모병
- UC San Diego McGrath Outpatient Pavilion - Hillcrest
-
San Diego, California, 미국, 92127
- 모병
- UC San Diego Medical Center - Rancho Bernardo
-
San Diego, California, 미국, 92103
- 모병
- UC San Diego Medical Center- Hillcrest
-
Vista, California, 미국, 92081
- 모병
- UC San Diego Medical Center - Vista
-
-
Illinois
-
Hinsdale, Illinois, 미국, 60521
- 모병
- Hope and Healing Clinical Research
-
New Lenox, Illinois, 미국, 60451
- 모병
- Hope and Healing Clinical Research
-
-
New Jersey
-
Basking Ridge, New Jersey, 미국, 07920
- 모병
- MSK Basking Ridge
-
Middletown, New Jersey, 미국, 07748
- 모병
- MSK Monmouth
-
Montvale, New Jersey, 미국, 07645
- 모병
- MSK Bergen.
-
-
New York
-
Commack, New York, 미국, 11725
- 모병
- MSK Commack
-
Harrison, New York, 미국, 10604
- 모병
- MSK Westchester
-
Long Island City, New York, 미국, 11101
- 모병
- Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy
-
New York, New York, 미국, 10065
- 모병
- Memorial Sloan Kettering Cancer Center
-
New York, New York, 미국, 10021
- 모병
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
-
Uniondale, New York, 미국, 11553
- 모병
- MSK Nassau
-
-
-
-
-
Porto Alegre, 브라질, 90610-000
- 모병
- Hospital São Lucas da PUCRS
-
São Paulo, 브라질, 01452-000
- 아직 모집하지 않음
- Centro Paulista de Oncologia Clínica
-
-
São Paulo
-
São Paulo, São Paulo, 브라질, 01321-001
- 모병
- Hospital Beneficência Portuguesa de São Paulo
-
-
-
-
-
Madrid, 스페인, 28041
- 모병
- Hospital Universitario 12 de Octubre
-
Seville, 스페인, 41013
- 모병
- Hospital Universitario Virgen Del Rocio
-
-
Catalunya [cataluña]
-
L'Hospitalet de Llobregat, Catalunya [cataluña], 스페인, 08908
- 모병
- Institut Català d'Oncologia - L'Hospitalet
-
-
-
-
HA Merkaz
-
Ramat Gan, HA Merkaz, 이스라엘, 5265601
- 모병
- Sheba Medical Center
-
-
Jerusalem
-
Jerusalem, Jerusalem, 이스라엘, 9103102
- 모병
- Shaare Zedek Medical Center
-
-
-
-
-
Bergamo, 이탈리아, 24125
- 모병
- Cliniche Gavazzeni S.p.A. - Humanitas Gavazzeni
-
-
ROME
-
Roma, ROME, 이탈리아, 00144
- 아직 모집하지 않음
- IRCCS Istituto Nazionale dei Tumori Regina Elena
-
-
Turin
-
Orbassano, Turin, 이탈리아, 10043
- 모병
- A.O.U. San Luigi Gonzaga
-
-
-
-
Kerala
-
Kottayam, Kerala, 인도, 686630
- 모병
- Caritas Hospital and Institute of Health Sciences
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, 인도, 110085
- 모병
- Rajiv Gandhi Cancer Institute And Research Centre
-
-
-
-
-
Osaka, 일본, 541-8567
- 모병
- Osaka International Cancer Institute(OICI)
-
-
Aichi-ken
-
Nagoya, Aichi-ken, 일본, 464-8681
- 모병
- Aichi Cancer Center Hospital
-
-
Okayama-ken
-
Kita, Okayama-ken, 일본, 700-8558
- 아직 모집하지 않음
- Okayama University Hospital
-
-
Osaka
-
Hirakata, Osaka, 일본, 573-1191
- 모병
- Kansai Medical University Hospital
-
-
Tokyo
-
Chūō, Tokyo, 일본, 104-0045
- 모병
- National Cancer Center - Tsukiji Campus
-
Kotoku, Tokyo, 일본, 135-8550
- 모병
- Japanese Foundation for Cancer Research
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, 중국, 100730
- 모병
- Peking Union Medical College Hospital
-
-
Fujian
-
Fuzhou, Fujian, 중국, 350014
- 모병
- Fujian Cancer Hospital
-
-
Henan
-
Zhengzhou, Henan, 중국, 450008
- 모병
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, 중국, 430048
- 모병
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
-
Jiangxi
-
Nanchang, Jiangxi, 중국, 330200
- 모병
- The First Affiliated Hospital of Nanchang University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 200030
- 모병
- Shanghai Chest Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, 중국, 310003
- 모병
- The first Affiliated Hospital, Zhejiang University School of Medicine
-
-
-
-
-
Lyon, 프랑스, 69373
- 모병
- Centre Léon Bérard
-
Marseille, 프랑스, 13915
- 모병
- Assistance Publique Hôpitaux de Marseille - Hôpital Nord
-
Villejuif, 프랑스, 94805
- 아직 모집하지 않음
- Institut Gustave Roussy
-
-
-
-
New South Wales
-
Westmead, New South Wales, 호주, 2145
- 아직 모집하지 않음
- Westmead Hospital
-
-
South Australia
-
Elizabeth Vale, South Australia, 호주, 5112
- 모병
- Calvary Connery Centre
-
-
Victoria
-
Heidelberg, Victoria, 호주, 3084
- 아직 모집하지 않음
- Warringal Private Hospital
-
-
-
-
-
Hong Kong, 홍콩
- 모병
- Queen Mary Hospital
-
Hong Kong, 홍콩
- 모병
- Prince of Wales Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male or female participants aged ≥18 years at the time of informed consent.
- Histologically or cytologically confirmed T-SCLC. Participant must have had a prior diagnosis of NSCLC with EGFR mutation which transformed to SCLC following the treatment with TKI(s).
- Participants have not received systemic therapy for T-SCLC.
- Have at least one measurable lesion as the target lesion based on RECIST v1.1.
- Have sufficient tumor tissue from the diagnosis of transformed SCLC available.
- Eastern Cooperative Oncology Group performance status of 0 or 1.
- Have a minimum life expectancy of >12 weeks.
- Clinical laboratory values at screening within acceptable limits, as defined in the protocol, including: 1) Hematology, 2) Liver function and 3) Renal function.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
-
Active or untreated CNS disease, including brain, brainstem, spinal cord, or meningeal metastases. Participants with definitively treated, clinically stable brain metastases may be eligible per protocol criteria. Participants with untreated asymptomatic brain metastases of longest diameter <1 cm are permitted if all of the following criteria are met: absence of neurological symptoms, no need for corticosteroids, and brain metastasis has no evidence of edema or hemorrhagic features.
-
Leptomeningeal disease
-
Clinically significant risk of hemorrhage or fistula, including tumor necrosis/cavitation, invasion or compression of major blood vessels, airways, or critical organs, or risk of tracheoesophageal or pleuroesophageal fistula
-
History of another malignancy (other than NSCLC) within 3 years prior to first dose, except for malignancies with negligible risk of metastasis or death (eg, adequately treated carcinoma in situ, nonmelanoma skin cancer)
-
Unresolved toxicity from prior anti-tumor therapy that has not recovered to Grade ≤1 per NCI CTCAE v5.0 (except alopecia or irreversible toxicities deemed stable)
-
History of allogeneic organ or hematopoietic stem cell transplantation
-
Active autoimmune disease requiring systemic treatment within the past 2 years (Stable replacement therapy and selected low-risk autoimmune conditions are permitted per protocol)
-
Interstitial lung disease (ILD), pneumonitis, or significant pulmonary disease, including:
- Prior or current non-infectious pneumonitis requiring systemic therapy
- DLCO <50% predicted
- Severe asthma, COPD, pulmonary embolism, or autoimmune lung involvement
-
Uncontrolled or clinically significant cardiovascular, cerebrovascular, metabolic, hepatic, or renal disease within 6 months prior to first dose
-
Baseline QTcF >480 msec
-
Major surgery or severe trauma within 4 weeks prior to first dose, or planned major surgery during the study
-
Clinically significant pleural effusion, pericardial effusion, or ascites requiring repeated drainage
-
History of significant bleeding disorders or recent major bleeding events
-
Clinically significant gastrointestinal conditions, including recent perforation, fistula, obstruction, or active bleeding
-
Active, uncontrolled, or symptomatic infection, including:
- Active TB
- Active hepatitis B or C
- Uncontrolled HIV infection
-
History of immunodeficiency
-
Severe hypersensitivity or allergic reactions to study intervention components or monoclonal antibodies
-
Psychiatric illness or medical condition, including recent suicidal ideation or behavior, that may increase risk or interfere with study participation
-
Prior anti-angiogenic therapy or other prohibited anti-tumor or immunomodulatory therapies per protocol-specified washout periods
-
Use of prohibited concomitant medications, including high-dose systemic corticosteroids, certain anticoagulants, or live vaccines within protocol-specified timeframes
-
Recent participation in another investigational study (within 30 days or 5 half-lives, whichever is longer)
-
Pregnant or breastfeeding participants, or unwillingness to comply with contraception requirements
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: PF-08634404
Participants will receive PF-08634404 in combination with chemotherapy intravenously, followed by maintenance therapy with PF-08634404. |
Injection for intravenous use Concentrate for solution for infusion
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Confirmed Objective Response Rate (ORR) as assessed by investigator based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
기간: From start of treatment until first documented CR or PR (approximately maximum up to 1 years)
|
Defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) is observed as best overall response. ORR using RECIST v1.1 as assessed by investigator. |
From start of treatment until first documented CR or PR (approximately maximum up to 1 years)
|
|
Number of Participants with Adverse Events (AEs)
기간: Up to 90 days after the last dose of treatment
|
Adverse Events (AEs) as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention. |
Up to 90 days after the last dose of treatment
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
PF-08634404에 대한 항약물 항체 발생률
기간: 치료의 마지막 투여 후 최대 37일
|
치료의 마지막 투여 후 최대 37일
|
|
|
약동학: 투여 전 및 투여 후 PF-08634404의 혈청 농도
기간: 치료 마지막 투여 후 최대 37일
|
치료 마지막 투여 후 최대 37일
|
|
|
Progression Free Survival (PFS) as assessed by investigator based on RECIST v1.1
기간: Up to approximately 2 years after completion of study treatment of last study participant
|
PFS is defined as the time from the date of randomization to the date of first documented disease progression, per RECIST v1.1, or death to any cause, whichever occurs first |
Up to approximately 2 years after completion of study treatment of last study participant
|
|
Number of participants with Laboratory abnormalities
기간: Up to 90 days after the last dose of treatment
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. |
Up to 90 days after the last dose of treatment
|
|
Duration of Response (DOR) as assessed by investigator based on RECIST v1.1
기간: Up to approximately 2 years after completion of study treatment of last study participant
|
DOR is defined as the time from the first documentation of objective response (CR or PR) to the date of first documentation of disease progression (PD) or death due to any cause. |
Up to approximately 2 years after completion of study treatment of last study participant
|
|
Overall Survival (OS)
기간: Up to approximately 2 years after completion of study treatment of last study participant
|
OS is defined as the time from the date of randomization to the date of death due to any cause. OS is secondary outcome measure in Phase 2 portion of the study. |
Up to approximately 2 years after completion of study treatment of last study participant
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Pfizer CT.gov Call Center, Pfizer
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- C6461014
- 2025-524686-24-00 (레지스트리 식별자: CTIS (EU))
- 2025 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .